10-Q: Haemonetics Reports Q3 2025 Results, Driven by Hospital Segment Growth

Haemonetics Corporation announces its Q3 2025 financial results, highlighting revenue growth driven by the Hospital segment, while Plasma and Blood Center segments face declines.

Summary

• Haemonetics Corporation reported net revenues of $348.5 million for the three months ended December 28, 2024, a 3.7% increase compared to $336.2 million for the same period in fiscal 2024.
• For the nine months ended December 28, 2024, net revenues were $1.03 billion, a 6.7% increase compared to $965.8 million for the same period in fiscal 2024.
• The Hospital segment drove revenue growth, while the Plasma and Blood Center segments experienced declines.
• Operating income increased by 28.4% to $59.0 million for the quarter and by 11.5% to $150.5 million for the nine-month period.
• Net income was $37.5 million, or $0.75 per basic share, for the quarter, and $109.7 million, or $2.16 per basic share, for the nine-month period.
• The company completed the acquisition of Attune Medical on April 1, 2024, for $187.7 million.
• Haemonetics divested its Whole Blood product line to GVS, S.p.A. on January 13, 2025, for up to $67.8 million.
• The company completed a $75.0 million share repurchase in October 2024, with $150.0 million remaining authorized for future repurchases.
• Haemonetics issued $700.0 million in convertible senior notes due 2029 and refinanced its credit facilities in April 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there are challenges in the Plasma and Blood Center segments, the strong growth in the Hospital segment, strategic acquisitions and divestitures, and active capital management contribute to a positive outlook.

Positives

• The Hospital segment is experiencing strong revenue growth, driven by acquisitions and increased demand.
• Operating income is increasing due to operating leverage and decreased performance-based compensation.
• The company is actively managing its capital structure through share repurchases and debt refinancing.
• The acquisition of Attune Medical expands the Hospital business unit's presence in electrophysiology.
• The company is actively managing its portfolio through the divestiture of the Whole Blood product line.

Negatives

• Plasma revenue is declining due to the CSL Plasma customer transition.
• Blood Center revenue is declining due to challenges in the Whole Blood business.
• The company is incurring costs related to acquisitions, integration, and digital transformation.
• Amortization of acquired intangible assets is increasing due to recent acquisitions.
• Interest expense is increasing due to the issuance of new convertible notes.

Risks

• The CSL Plasma customer transition continues to negatively impact Plasma revenue.
• The company faces challenges in the Blood Center segment due to declining demand for Whole Blood products.
• Integration of acquired companies and implementation of a new ERP system could present operational challenges.
• Foreign exchange rate fluctuations could negatively impact financial results.
• The company is subject to legal proceedings, including a patent infringement claim.

Future Outlook

The company anticipates sales of approximately $100.0 million to CSL in fiscal 2025.

Industry Context

Haemonetics operates in the global healthcare industry, providing medical technology solutions for blood and plasma component collection, the surgical suite, and hospital transfusion services; the company competes with other medical device manufacturers and healthcare providers, and is subject to industry trends such as healthcare cost containment and regulatory changes.

Comparison to Industry Standards

• It is difficult to make a direct comparison to industry standards without knowing the specific growth rates and profitability metrics of Haemonetics' direct competitors in each of its segments (Plasma, Blood Center, and Hospital).
• However, the Hospital segment's growth appears strong compared to the overall medical device market, which typically grows in the mid-single digits.
• Companies like Medtronic, Abbott, and Boston Scientific are major players in the broader medical device industry, but their segment-specific performance would need to be analyzed for a more accurate comparison.
• The decline in the Plasma segment is notable and may be compared to the performance of companies like CSL Behring and Grifols, which are major players in the plasma collection and fractionation market.
• The divestiture of the Whole Blood product line suggests a strategic shift to focus on higher-growth areas, which is a common practice among medical device companies.

Legal Proceedings

• The company is involved in a legal proceeding related to the Illinois Biometric Information Privacy Act (BIPA), for which a settlement has been reached and payment issued.
• A complaint was filed in the U.S. District Court for the District of Delaware by Knoninklijke Philips N.V. and IP2IPO Innovations, Ltd. against OpSens, OpSens Medical, Inc., a wholly-owned subsidiary of OpSens, and Haemonetics alleging patent infringement.

Stakeholder Impact

• Shareholders: The share repurchase program and debt refinancing aim to enhance shareholder value.
• Customers: The acquisition of Attune Medical and the focus on the Hospital segment aim to provide innovative medical technology solutions.
• Employees: Restructuring programs and portfolio rationalization initiatives may impact employment.

Next Steps

• Continue to manage the CSL Plasma customer transition.
• Focus on growth opportunities in the Hospital segment.
• Integrate acquired companies and implement the new ERP system.
• Monitor and manage foreign exchange rate exposure.
• Defend against the patent infringement claim.

Key Dates

Keywords

Haemonetics, financial results, Q3 2025, Hospital segment, Plasma, Blood Center, revenue, operating income, net income, acquisition, divestiture, share repurchase, convertible notes, credit facilities